## Two neurostructural subtypes: results of machine learning on brain images from 4,291 individuals with schizophrenia

2 3

1

4 Yuchao Jiang<sup>1,2</sup>, Cheng Luo<sup>3,4,5</sup>, Jijun Wang<sup>6</sup>, Lena Palaniyappan<sup>7</sup>, Xiao Chang<sup>1,2</sup>, Shitong Xiang<sup>1,2</sup>, Jie 5 Zhang<sup>1,2</sup>, Mingjun Duan<sup>3</sup>, Huan Huang<sup>3</sup>, Christian Gaser<sup>8,9,10</sup>, Kiyotaka Nemoto<sup>11</sup>, Kenichiro Miura<sup>12</sup>, 6 Ryota Hashimoto<sup>12</sup>, Lars T. Westlye<sup>13,14,15</sup>, Genevieve Richard<sup>13,14,15</sup>, Sara Fernandez-Cabello<sup>13,14,15</sup>, 7 Nadine Parker<sup>14</sup>, Ole A. Andreassen<sup>14</sup>, Tilo Kircher<sup>16</sup>, Igor Nenadić<sup>16</sup>, Frederike Stein<sup>16</sup>, Florian Thomas-8 Odenthal<sup>16</sup>, Lea Teutenberg<sup>16</sup>, Paula Usemann<sup>16</sup>, Udo Dannlowski<sup>17</sup>, Tim Hahn<sup>17</sup>, Dominik Grotegerd<sup>17</sup>, 9 Susanne Meinert<sup>17</sup>, Rebekka Lencer<sup>17,68,69</sup>, Yingying Tang<sup>6</sup>, Tianhong Zhang<sup>6</sup>, Chunbo Li<sup>6</sup>, Weihua 10 Yue<sup>18,19,20</sup>, Yuyanan Zhang<sup>18</sup>, Xin Yu<sup>18</sup>, Enpeng Zhou<sup>18</sup>, Ching-Po Lin<sup>21</sup>, Shih-Jen Tsai<sup>22</sup>, Amanda L. 11 Rodrigue<sup>23</sup>, David Glahn<sup>23</sup>, Godfrey Pearlson<sup>24</sup>, John Blangero<sup>25</sup>, Andriana Karuk<sup>26,27</sup>, Edith Pomarol-12 Clotet<sup>26,27</sup>, Raymond Salvador<sup>26,27</sup>, Paola Fuentes-Claramonte<sup>26,27</sup>, María Ángeles Garcia-León<sup>26,27</sup>, 13Gianfranco Spalletta<sup>28</sup>, Fabrizio Piras<sup>28</sup>, Daniela Vecchio<sup>28</sup>, Nerisa Banaj<sup>28</sup>, Jingliang Cheng<sup>29</sup>, Zhening 14 Liu<sup>30</sup>, Jie Yang<sup>30</sup>, Ali Saffet Gonul<sup>31</sup>, Ozgul Uslu<sup>32</sup>, Birce Begum Burhanoglu<sup>32</sup>, Aslihan Uyar Demir<sup>31</sup>, Kelly Rootes-Murdy<sup>33</sup>, Vince D. Calhoun<sup>33</sup>, Kang Sim<sup>34,35,36</sup>, Melissa Green<sup>37</sup>, Yann Quidé<sup>38</sup>, Young Chul 15Chung<sup>39,40,41</sup>, Woo-Sung Kim<sup>39,41</sup>, Scott R. Sponheim<sup>42,43,44</sup>, Caroline Demro<sup>43</sup>, Ian S. Ramsay<sup>43</sup>, Felice 16 17lasevoli<sup>45</sup>, Andrea de Bartolomeis<sup>45</sup>, Annarita Barone<sup>45</sup>, Mariateresa Ciccarelli<sup>45</sup>, Arturo Brunetti<sup>46</sup>, Sirio Cocozza<sup>46</sup>, Giuseppe Pontillo<sup>46</sup>, Mario Tranfa<sup>46</sup>, Min Tae M. Park<sup>47,48</sup>, Matthias Kirschner<sup>49,50</sup>, Foivos 18 19 Georgiadis<sup>50</sup>, Stefan Kaiser<sup>49</sup>, Tamsyn E Van Rheenen<sup>51,52</sup>, Susan L Rossell<sup>52</sup>, Matthew Hughes<sup>52</sup>, 20 William Woods<sup>52</sup>, Sean P Carruthers<sup>52</sup>, Philip Sumner<sup>52</sup>, Elysha Ringin<sup>53</sup>, Filip Spaniel<sup>53</sup>, Antonin Skoch<sup>53,54</sup>, David Tomecek<sup>53,55,56</sup>, Philipp Homan<sup>57,58</sup>, Stephanie Homan<sup>59,60</sup>, Wolfgang Omlor<sup>57</sup>, 21 22 Giacomo Cecere<sup>57</sup>, Dana D Nguyen<sup>61</sup>, Adrian Preda<sup>62</sup>, Sophia Thomopoulos<sup>63</sup>, Neda Jahanshad<sup>63</sup>, 23 Long-Biao Cui<sup>64</sup>, Dezhong Yao<sup>3,4,5</sup>, Paul M. Thompson<sup>63</sup>, Jessica A. Turner<sup>65</sup>, Theo G.M. van Erp<sup>66,67</sup>, 24Wei Cheng<sup>1,2,70,71,72</sup>, ENIGMA Schizophrenia Consortium, ZIB Consortium, Jianfeng Feng<sup>1,2,72,73,74,75,76,\*</sup> 25 26 1 Institute of Science and Technology for Brain Inspired Intelligence, Fudan University, Shanghai, China. 272 Key Laboratory of Computational Neuroscience and Brain Inspired Intelligence (Fudan University), 28 Ministry of Education, Shanghai, China. 29 3 The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, School 30 of life Science and technology, University of Electronic Science and Technology of China, Chengdu, 31 China. 32 4 High-Field Magnetic Resonance Brain Imaging Key Laboratory of Sichuan Province, Center for 33 Information in Medicine, University of Electronic Science and Technology of China, Chengdu, China. 34 5 Research Unit of NeuroInformation (2019RU035), Chinese Academy of Medical Sciences, Chengdu, 35 China. 36 6 Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong 37 University School of Medicine, Shanghai, China. 7 Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montréal, 38 39 Canada. 40 8 Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany. 41 9 Department of Neurology, Jena University Hospital, Jena, Germany. 42 10 German Center for Mental Health (DZPG), Site Jena-Magdeburg-Halle, Germany. 43 11 Department of Psychiatry, Division of Clinical Medicine, Institute of Medicine, University of Tsukuba, 44 Tsukuba, 305-8575, Japan.

1

- 45 12 Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of
- 46 Neurology and Psychiatry, Kodaira, 187-8553, Japan.
- 47 13 Department of Psychology, University of Oslo, Oslo, Norway.
- 48 14 NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital & Institute of
- 49 Clinical Medicine, University of Oslo, Oslo, Norway.
- 50 15 KG Jebsen Centre for Neurodevelopmental Disorders, University of Oslo and Oslo University
- 51 Hospital, Oslo, Norway.
- 52 16 Department of Psychiatry and Psychotherapy, Philipps Universität Marburg, Rudolf-Bultmann-Str. 8,
- 53 35039 Marburg, Germany.
- 54 17 Institute for Translational Psychiatry, University of Münster, Münster, Germany.
- 55 18 Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of
- 56 Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking
- 57 University Sixth Hospital), Beijing, PR China.
- 58 19 Chinese Institute for Brain Research, Beijing, PR China.
- 59 20 PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, PR China.
- 60 21 Institute of Neuroscience, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- 61 22 Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.
- 62 23 Department of Psychiatry, Boston Children's Hospital, Harvard Medical School, Boston MA, USA.
- 63 24 Olin Neuropsychiatry Research Center, Institute of Living, Hartford, CT, USA.
- 64 25 Department of Human Genetics and South Texas Diabetes and Obesity Institute, School of Medicine,
- 65 University of Texas of the Rio Grande Valley, Brownsville, TX, USA.
- 66 26 FIDMAG Germanes Hospitalàries Research Foundation, Barcelona 08035, Spain.
- 67 27 Centro de Investigación Biomédica en Red de Salud Mental, Instituto de Salud Carlos III, Spain.
- 68 28 Neuropsychiatry Laboratory, Department of Clinical Neuroscience and Neurorehabilitation, IRCCS
- 69 Santa Lucia Foundation, Rome, Italy.
- 29 Department of MRI, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- 30 National Clinical Research Center for Mental Disorders, Department of Psychiatry, The Second
- 72 Xiangya Hospital of Central South University, Changsha, Hunan, PR China.
- 73 31 Ege University School of Medicine Department of Psychiatry, SoCAT Lab, Izmir, Turkey.
- 74 32 Ege University Institute of Health Sciences Department of Neuroscience, Izmir, Turkey.
- 75 33 Tri-institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS)
- 76 [Georgia State University, Georgia Institute of Technology, Emory University], Atlanta, GA, USA.
- 77 34 West Region, Institute of Mental Health, Singapore.
- 78 35 Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- 79 36 Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
- 80 37 School of Clinical Medicine, University of New South Wales, Sydney, Australia.
- 81 38 School of Psychology, University of New South Wales, Sydney, Australia.
- 82 39 Department of Psychiatry, Jeonbuk National University Hospital, Jeonju, Korea.
- 83 40 Department of Psychiatry, Jeonbuk National University, Medical School, Jeonju, Korea.
- 84 41 Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute
- 85 of Jeonbuk National University Hospital, Jeonju, Korea.
- 86 42 Minneapolis VA Medical Center, University of Minnesota, Minneapolis, MN, USA.
- 43 Department of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis, MN, USA.
- 88 44 Department of Psychology, University of Minnesota, Minneapolis, MN, USA.

- 89 45 Section of Psychiatry Department of Neuroscience University "Federico II", Naples, Italy.
- 90 46 Department of Advanced Biomedical Sciences University "Federico II", Naples, Italy.
- 91 47 Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
- 92 48 Centre for Addiction and Mental Health, Toronto, Canada.
- 93 49 Division of Adult Psychiatry, Department of Psychiatry, University Hospitals of Geneva, Switzerland.
- 94 50 Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital University of
- 95 Zurich, Switzerland.
- 96 51 Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne, Melbourne,
- 97 Australia.
- 98 52 Centre for Mental Health and Brain Sciences, School of Health Sciences, Swinburne University,
- 99 Melbourne, Australia.
- 100 53 National Institute of Mental Health, Klecany, Czech Republic.
- 101 54 MR Unit, Department of Diagnostic and Interventional Radiology, Institute for Clinical and
- 102 Experimental Medicine, Prague, Czech Republic.
- 103 55 Institute of Computer Science, Czech Academy of Sciences, Prague, Czech Republic.
- 104 56 Faculty of Electrical Engineering, Czech Technical University in Prague, Prague, Czech Republic.
- 105 57 Psychiatric Hospital, University of Zurich, Zurich, Switzerland.
- 106 58 Neuroscience Center Zurich, University of Zurich & Swiss Federal Institute of Technology Zurich,
- 107 Zurich, Switzerland.
- 108 59 Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital
- 109 Zurich, Switzerland.
- 110 60 Experimental Psychopathology and Psychotherapy, Department of Psychology, University of Zurich,
- 111 Switzerland.
- 112 61 Department of Pediatrics, University of California Irvine, Irvine, California, USA.
- 113 62 Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, California,
- 114 USA.
- 115 63 Imaging Genetics Center, Stevens Neuroimaging & Informatics Institute, Keck School of Medicine,
- 116 University of Southern California, Los Angeles, CA, USA.
- 117 64 Department of Clinical Psychology, Fourth Military Medical University, Xi'an, PR China.
- 118 65 Psychiatry and Behavioral Health, Ohio State Wexner Medical Center, Columbus, OH, USA.
- 119 66 Clinical Translational Neuroscience Laboratory, Department of Psychiatry and Human Behavior,
- 120 University of California Irvine, Irvine Hall, room 109, Irvine, CA, 92697-3950, USA.
- 121 67 Center for the Neurobiology of Learning and Memory, University of California Irvine, 309 Qureshey
- 122 Research Lab, Irvine, CA, 92697, USA.
- 123 68 Department of Psychiatry and Psychotherapie and Center for Brain, Behavior and Metabolism,
- 124 Lübeck University, Lübeck, Germany.
- 125 69 Institute for Transnational Psychiatry and Otto Creutzfeldt Center for Behavioral and Cognitive
- 126 Neuroscience, University of Münster, Münster, Germany.
- 127 70 Shanghai Medical College and Zhongshan Hospital Immunotherapy Technology Transfer Center,
- 128 Shanghai, China.
- 129 71 Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
- 130 72 Fudan ISTBI—ZJNU Algorithm Centre for Brain-Inspired Intelligence, Zhejiang Normal University,
- 131 Jinhua, China.
- 132 73 MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China.

4

- 133 74 Zhangjiang Fudan International Innovation Center, Shanghai, China.
- 134 75 School of Data Science, Fudan University, Shanghai, China.
- 135 76 Department of Computer Science, University of Warwick, Coventry CV4 7AL, UK.
- 136 \* Corresponding Authors to: Jianfeng Feng, jffeng@fudan.edu.cn

#### 137 Abstract

138 Machine learning can be used to define subtypes of psychiatric conditions based on shared 139 clinical and biological foundations, presenting a crucial step toward establishing 140 biologically based subtypes of mental disorders. With the goal of identifying subtypes of 141 disease progression in schizophrenia, here we analyzed cross-sectional brain structural 142 magnetic resonance imaging (MRI) data from 4,291 individuals with schizophrenia (1,709 143 females, age=32.5 years±11.9) and 7,078 healthy controls (3,461 females, age=33.0 144 years±12.7) pooled across 41 international cohorts from the ENIGMA Schizophrenia 145 Working Group, non-ENIGMA cohorts and public datasets. Using a machine learning 146 approach known as Subtype and Stage Inference (SuStaIn), we implemented a brain 147 imaging-driven classification that identifies two distinct neurostructural subgroups by 148 mapping the spatial and temporal trajectory of gray matter (GM) loss in schizophrenia. 149 Subgroup 1 (n=2,622) was characterized by an early cortical-predominant loss (ECL) with 150enlarged striatum, whereas subgroup 2 (n=1,600) displayed an early subcortical-151 predominant loss (ESL) in the hippocampus, amygdala, thalamus, brain stem and striatum. 152These reconstructed trajectories suggest that the GM volume reduction originates in the 153Broca's area/adjacent fronto-insular cortex for ECL and in the hippocampus/adjacent 154medial temporal structures for ESL. With longer disease duration, the ECL subtype exhibited a gradual worsening of negative symptoms and depression/anxiety, and less of 155156 a decline in positive symptoms. We confirmed the reproducibility of these imaging-based 157subtypes across various sample sites, independent of macroeconomic and ethnic factors 158 that differed across these geographic locations, which include Europe, North America and 159East Asia. These findings underscore the presence of distinct pathobiological foundations 160 underlying schizophrenia. This new imaging-based taxonomy holds the potential to identify 161 a more homogeneous sub-population of individuals with shared neurobiological attributes, 162 thereby suggesting the viability of redefining existing disorder constructs based on 163 biological factors.

164

Keywords: schizophrenia; structural MRI; artificial intelligence; subtype; ENIGMA; brain
gray matter

## 167 **1. Introduction**

168 A key goal of biological psychiatry is to define biological subtypes of major mental 169 disorders, based on objective measures derived from imaging and other biomarkers [1]. In 170psychiatry, redefining subtypes of psychiatric disorders based on neural mechanisms 171 augmenting clinical behavioral criteria presents significant benefits. By using biological 172 characteristics to more efficiently identify biologically homogeneous clinical cohorts, clinical 173trials could more effectively discern the biological effects of a given intervention. Artificial 174 intelligence (AI) methods such as machine learning can be applied to brain imaging [2] to 175categorize individuals based on their profiles of brain metrics, and holds great potential for 176 revealing the underlying neurobiological mechanisms associated with disorder subtypes 177 [3].

178 Schizophrenia is one of the most severely disabling psychiatric disorders with a life-179 time prevalence of 1%; it affects approximately 26 million people worldwide [4]. The 180 etiology of schizophrenia is still not fully understood. Current knowledge implicates multiple 181 neurobiological mechanisms and pathophysiologic processes [5, 6]. Furthermore, people 182 diagnosed with schizophrenia show a substantial heterogeneity in clinical symptoms [7], 183 disease progression [8], treatment response [9], and other biological markers [10, 11]. In 184 addition, currently available treatments are not aligned with specific pathophysiological 185 pathways/targets, which limits effectiveness of treatment selection [12]. Establishing a new 186 taxonomy by identifying distinct subtypes based on neurobiological data could help resolve 187 some of these heterogeneity-induced challenges.

188 Machine learning algorithms are increasingly used to subtype brain disorders [13-16]. 189 Prior studies have primarily focused on grouping individuals into distinct categories without 190 considering disease progression [17, 18]. A major obstacle to identifying distinct patterns 191 of neuro-pathophysiological progression (referred to as progression subtypes) stems from 192 the lack of sufficient longitudinal data covering the lifespan of the disorder. Recently, a 193 novel data-driven machine learning approach known as Subtype and Stage Inference 194 (SuStaln) was introduced [19]. SuStaln uses a large number of cross-sectional 195 observations, derived from single time-point MRI scans, to identify clusters (subtypes) of 196 individuals with common trajectory of disease progression (i.e., the sequence of MRI 197 abnormalities across different brain regions) in brain disorders [20-22]. By applying 198 SuStaIn to MRI data from individuals with schizophrenia, primarily collected from the 199 Chinese population, we found that the progression of gray matter loss in schizophrenia can 200 be better characterized through two distinct phenotypes: one characterized by a cortical-201 predominant progression, originating in the Broca's area/fronto-insular cortex, and another 202 marked by a subcortical-predominant progression, starting in the hippocampus [22]. Such 203 brain-based taxonomies may reflect neurostructural subtypes with shared 204 pathophysiological foundations, with relevance for neurobiological classification [22]. 205 However, the generalisability of the two neurostructural subtypes to diverse populations 206 outside of China, and external validation of the subgrouping is required before applying 207 this knowledge to stratify clinical trials.

208 The Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA, 209 http://enigma.ini.usc.edu) consortium is dedicated to conducting large-scale analyses by 210 pooling brain imaging data from research teams worldwide, using standardized image 211 processing protocols. Previously, ENIGMA published findings revealing thinner cerebral 212 cortex, smaller surface area, and altered subcortical volumes in schizophrenia compared 213 to controls [23, 24]. Here, we included structural MRI data obtained from 4,291 individuals 214 diagnosed with schizophrenia and 7,078 healthy controls from 41 international cohorts 215 from ENIGMA schizophrenia groups worldwide and other non-ENIGMA datasets 216 (Supplementary Table 1). The large sample size allowed us to conduct systematic and 217 comprehensive analyses to verify the reproducibility and generality of neurostructural 218 subtypes of schizophrenia across regions/locations and disease stages. This study's aims 219 were: (1) to validate the two neurostructural subtypes with distinct trajectories of neuro-220 pathophysiological progression in schizophrenia, (2) to verify the reproducibility and 221 generality of the neurostructural subtypes, in subsamples across the world and across 222 disease stages, and (3) to characterize subtype-specific signatures in terms of 223 neuroanatomy and clinical symptomatic trajectory.

224 Together, these analyses aim to create a new, easily accessible (with a single 225 anatomical MRI), interpretable (based on 'progressive' pathology) and robustly 226 generalizable (across ethnic, sex and language differences) taxonomy of subtypes that 227 share common neurobiological mechanisms in schizophrenia. If proven effective, other 228 complex neuropsychiatric disorders with high heterogeneity [25, 26], such as major 229 depressive disorder, autism spectrum disorder, and obsessive-compulsive disorder, could 230 also benefit from such a subtyping paradigm. This has the potential to transition the field 231 of psychiatry from syndrome-based to both syndrome- and biology-based stratifications of 232 mental disorders.

## 233 **2. Results**

#### 234 2.1 Two biotypes with distinct pathophysiological progression trajectories

235Distinct patterns of spatiotemporal progression of pathophysiological progression 236 were identified using SuStaIn, based on cross-sectional MRI data from 4,222 individuals 237 diagnosed with schizophrenia (1,683 females, mean age= $32.4 \pm 11.9$  years) and 7,038 238 healthy subjects (3,440 females, mean age=33.0±12.6 years) (Table.1). A 2-fold cross-239 validation procedure resulted in an optimal number of K=2 clusters (subtypes) as 240 determined by the largest Dice coefficient (Fig.1a), indicating the best consistency of the 241 subtype labeling across all individuals between for a model in two independent 242 schizophrenia populations. Fig.1b shows that only 1.2% of people were moved from 243 subtype 1 to subtype 2, and 7.5% were moved from subtype 2 to subtype 1, indicating that 244 91.3% of individuals' subtype labels were consistent between the SuStaIn classifications 245from two non-overlapping data folds. These findings suggest the presence of two stable 246 schizophrenia biotypes with distinct 'trajectories' of pathophysiological progression (here 247 we put trajectory in quotes as the typical sequence of disease progression is reconstructed 248 from cross-sectional data).

249 Region of interest (ROI)-wise gray matter volume (GMV) z-scores, at each stage of 250 the 'trajectory' for each subtype, show the sequence of regional volume loss across the 17 251brain regions for each 'trajectory' (Fig.1c). To visualize the spatiotemporal pattern of each 252 'trajectory', z-score whole brain images were mapped to a glass brain template (Fig.1d). 253 These maps show a progressive pattern of spatial expansion along with later 'temporal' 254stages of pathological progression distinct for each 'trajectory'. Specifically, 'trajectory' 1 255 displayed an 'early cortical-predominant loss' biotype. It was characterized by an initial 256 reduction in Broca's area, followed by adjacent fronto-insular regions, then extending to 257the rest of the neocortex, and finally to the subcortex (Fig.1d). Conversely, 'trajectory' 2 258 exhibited an 'early subcortical-predominant loss' biotype where volume loss began in the 259 hippocampus, spread to the amygdala and parahippocampus, and then extended to the 260 accumbens and caudate before affecting the cerebral cortex (Fig.1d). The two 'trajectories' 261 were highly consistent with our previous findings in a predominantly Chinese schizophrenia 262 cohort [22]. The phenotypic subtypes, based on the different pathophysiological 263 'trajectories', are thus replicated in a large cross-geography sample, confirming the 264 presence of two different neuropathological pathways with different anatomical origins in 265 schizophrenia [22].

266

#### 267 2.2 Trajectories are repeated in first-episode and medication-naïve samples

268 The sample size of this study was large enough to allow further exploratory analyses 269 to identify pathophysiological progression trajectories in more homogeneous subsamples 270 of schizophrenia. Here, we re-estimated the SuStaln 'trajectories' based on a subsample 271of data from individuals with first-episode schizophrenia with illness duration less than two 272 years (N=1,122; 513 females, mean age=25.4  $\pm$  8.6 years), and a subsample of 273 medication-naïve individuals with schizophrenia (N=718, 353 females, mean age=23.7 $\pm$ 274 7.8 years) (Supplementary Table 3). In both subsamples, we replicated the two 275'trajectories' with either the Broca's area or the hippocampus as the sites of origin

(Extended Data Fig.1), indicating that the two initiating regions - ranking ahead other regional deficits - are the pathological effects of the disease itself, rather than medicationinduced effects. Broca's area and the hippocampus may therefore be candidate targets for intervention in schizophrenia, as these two brain regions were affected early in the disease process.

281

#### 282 **2.3** Trajectories are reproducible for samples from different parts of the world

283 To examine whether the 'trajectories' were reproducible for samples from different 284 parts of the world, we divided all samples into several sub-cohorts based on where the 285samples were obtained (Extended Data Fig.5). Here, samples from China, Japan, South 286 Korea and Singapore were classified into the East Asian ancestry (EAS) cohort. Samples 287 from Europe, the United States, Canada and Australia were classified into the European 288 ancestry (EUR) cohorts (Supplementary Table 4). In addition, Chinese, Japanese, 289 European and North American cohorts were further classified by their site locations by their 290 site locations in terms of geographic distribution (Supplementary Table 4). Such a division 291 was based on the similar ethnic or environmental factors for each country, region, or 292 continent and the size of subsample, which need to be sufficient to conduct a reliable 293 inference of the SuStaIn trajectory. We found that two 'trajectories' (the optimal number 294 was also K=2, which separately re-estimated in each cohort) - with Broca's area leading 295and the hippocampus leading - were also repeated in EAS (Fig.2a) and EUR (Fig.2b) 296 cohorts. In addition, the spatiotemporal pattern of each 'trajectory' showed strong, 297 significant correlations between the EAS and EUR cohorts ('trajectory' 1, r=0.948, p<0.001; 298 'trajectory' 2, r=0.842, p<0.001; Spearman correlation test). This high level of similarity in 299 the trajectories was also observed between cohorts from other locations (Fig.2c). This 300 suggests that the two biotypes with distinct 'trajectories' of pathophysiological progression 301 in schizophrenia are robust, and their classification patterns are independent of macro-302 environmental or ethnogenetic factors.

303

# 304 2.4 Trajectories are associated with neurophysiological, pathological and 305 neuropsychological progressions in schizophrenia

306 The SuStain calculated the probability of each patient belonging to a specific 307 'trajectory' and further assigned them to a sub-stage within that trajectory. Individuals who 308 were assigned to the later stages of the 'trajectory' showed significant correlation with less 309 GMV of Broca's area (Fig.1e, r=0.651, p<0.0001) and hippocampus (Fig.1f, r=0.615, 310 p<0.0001). In addition, the later stages were correlated with longer disease duration 311 (Fig.1g, r=0.105, p<0.0001), worse negative symptoms (Fig.1h, r=0.101, p<0.0001) and 312 worse cognitive symptoms (Fig.1i, r=0.080, p=0.004). These results suggest that the 313 SuStaIn 'trajectory' reflects the underlying neural progression in schizophrenia.

314

#### 315 **2.5 Subtype-specific signatures in neuroanatomical pathology**

To characterize subtype-specific neuroanatomical signatures, we assessed regional morphological measures using FreeSurfer in a subsample including 1,840 individuals with schizophrenia and 1,780 healthy controls. A total of 330 regional morphological measures

in cortical thickness, cortical surface area, cortical volume, subcortical volume and subregion segmentation were quantified (see Methods).

321 Regional morphological z-scores (i.e., normative deviations from healthy control group) 322 for each subtype were computed and compared (Fig.3). Morphological z-scores of all brain 323 regions and inter-subtype comparisons are provided in the Supplementary Table S5. 324 Briefly, compared to healthy controls, average cortical volume/area reduction was only 325 observed in subtype 1 (Extended Data Fig.2a-b), though both subtype 1 and subtype 2 326 exhibited a moderate reduction in average cortical thickness (Extended Data Fig.2c). 327 Additionally, largest effects for cortical thickness/volume/area were located within the 328 superior frontal regions for subtype 1 and in the superior/medial temporal regions for 329 subtype2 (Supplementary Table S5). As for subcortical volume, larger effects for volumes 330 of hippocampus, amygdala, thalamus, accumbens and brain stem were observed in 331 subtype 2 compared to subtype 1 (Extended Data Fig.2d-h). The hippocampal/amygdala 332 subregions with the most significant reduction for subtype 2 were located in the molecular 333 layer and cortico-amygdaloid transition area (Extended Data Fig.3-4). Interestingly, we 334 observed that, compared to healthy controls, the striatum (i.e., caudate, putamen) was 335 larger among subtype 1 patients and smaller among subtype 2 patients (Extended Data 336 Fig.2i-j). The difference in the striatum between the two subtypes was also replicated in a 337 subsample of medication-naive individuals with schizophrenia (Supplementary Table S6). 338 The main findings of subtype-specific neuroanatomical signatures are described in Table 339 2. Taken together, subtype 1 exhibited greater deficits in cortical morphology but 340 enlargement volume of striatum, whereas subtype 2 displayed more severe volume loss in 341 the subcortical regions including hippocampus, amygdala, thalamus, brain stem as well as 342 the striatum.

343

#### 344 **2.6 Clinical characterization of subtypes**

345 A total of 2,622 (62.1%) individuals with schizophrenia were assigned to subtype 1 and the remaining 1,600 patients (37.9%) were assigned to subtype 2. The two subtypes 346 347 exhibit no significant difference in the age, sex, illness duration or PANSS scores (Table 348 1). To further characterize the psychotic symptomatic trajectory as disease progresses for 349 each subtype, we further defined three subgroups according to illness duration (early stage: 350 <2 years; middle stage: 2-10 years; late stage: >10 years). The results suggested distinct 351 trajectories of psychotic symptoms between the two subtypes (Fig.4 and Table 3). 352 Specifically, lower positive symptom severity was observed in late stage patients compared 353 early stage patients in both subtypes (subtype 1, F=37.4, p=1.60e-16; subtype2, F=41.9, 354 p=4.68e-18); however, at the late stage, subtype 1 exhibited worse positive symptom 355 compared to subtype 2 (t=2.8, p=0.005). With the increase of the disease course, subtype 356 1 showed a gradual worsening of negative symptom (F=4.6, p=9.98e-3), whereas the 357 negative symptoms of subtype 2 remained stable across the three stages of the disease 358 course (F=0.1, p=0.884). Additionally, a gradual worsening of depression/anxiety was only 359 observed in subtype 1 (F=5.9, p=2.86e-3), which showed worse depression/anxiety at the 360 late stage, compared to subtype 2 (t=2.1, p=0.036).

## 361 **3. Discussion**

362 Our study, applying a machine learning algorithm to brain MRI data from over 4,000 363 individuals with schizophrenia, has revealed two distinct neurostructural subtypes based 364 on patterns of neuro-pathological progression. These subtypes are reproducible and 365 generalizable across different subsamples and illness stages, independent of 366 macroeconomic and ethnic factors that differed across collection locations. Specific 367 patterns of neuroanatomical pathology for each subtype were uncovered. Subtype 1 is 368 characterized by early cortical-predominant loss that first occurs in the Broca's area/fronto-369 insular cortex, and shows adverse signatures in cortical morphology and an enlarged 370 striatum. In contrast, subtype 2 is marked by early subcortical-predominant loss that first 371 appears in the hippocampus, and displays significant volume loss in subcortical regions, 372 including the hippocampus, amygdala, thalamus, brain stem and striatum. Additionally, we 373 observed distinct trajectories of specific symptoms clusters in these two subtypes: as 374 disease progresses, subtype 1 exhibited a gradual worsening of negative and 375 depression/anxiety symptoms, and less of a decline in positive symptoms compared to 376 subtype 2.

377 Despite the growing body of evidence pointing to group-level gray matter volume 378 deficits in various brain regions - especially in frontal and temporal regions - as well as 379 altered subcortical volume in schizophrenia [27], substantial individual variations persist 380 within this population [11, 28]. These inter-individual differences in brain structure may stem 381 from two primary sources of variation. First, differences in underlying etiology and 382 pathogenesis could result in varying clinical characteristics (referred to as phenotypic 383 heterogeneity) [6, 29]. Second, relative differences among subjects in the stage of dynamic 384 progression (known as temporal heterogeneity) could further increase differences in the 385 clinical presentation [30, 31]. Such variations suggest that the pathological progression of 386 schizophrenia might not be attributed to a single unified pathophysiological process. 387 Indeed, our neurostructural subtypes uncovered two patterns of gray matter loss trajectory 388 through brain structural imaging. Several studies also reported dynamic patterns of 389 accelerated gray matter loss over time in individuals with schizophrenia [32, 33]. In addition, 390 staging of trajectory within subtype reflects the underlying neurophysiological, pathological 391 and neuropsychological progressions in schizophrenia. Furthermore, we demonstrated 392 that the phenotypic difference in the intrinsic neuro-pathophysiological trajectory was 393 reproducible across samples worldwide, independent of macroeconomic and ethnic factors 394 that differed across these sites.

395 The Broca's area/fronto-insular cortex and hippocampus are identified separately in 396 subtype 1 and subtype 2 as the first regions to show gray matter deficits. This is consistent 397 with our prior finding based on individuals with schizophrenia primarily collected from the 398 Chinese population [22]. Furthermore, the current study replicates the same two primary 399 regions in a medication-naïve and a first-episode cohort, suggesting that these 400 neuropathological changes are a reflection of the disease process, rather than medication 401 effects. Broca's area and the fronto-insular cortex have been extensively implicated in 402 schizophrenia [34], supporting Crow's linguistic primacy hypothesis [35] and a triple-403 network model of the disorder [36]. Moreover, in individuals with psychosis, reductions in

404 the inferior frontal cortex preceding the initial psychotic episode have been reported [37, 405 38]. A prior study reported reduced dopamine release in the prefrontal cortex in patients 406 with schizophrenia [39]. In relation to hippocampal pathology, research has emphasized 407 the hippocampus as one of the initial regions to display volumetric loss in schizophrenia 408 [40, 41]. The hippocampus is thought to be involved in potential glutamatergic dysfunction 409 in schizophrenia [6]. Decreased levels of the NMDA co-agonist D-serine were linked to 410 neurobiological alterations similar to those seen in schizophrenia, including hippocampal 411 volume loss [42]. These findings offer evidence regarding the specific neuroanatomical 412 locations where gray matter loss is first observed in the schizophrenia subtypes. These 413 two potential origins could also offer a new viewpoint on the pathological 'spread' of the disorder. 414

415 The new subtyping method employed exhibits high potential for distinguishing 416 neurostructural subtypes with shared pathophysiological foundations. Notably, subtype 1 417 displayed larger volume of the striatum, while subtype 2 demonstrated reduced volume. 418 The striatum plays a key role in the dopamine system, which contributes to psychotic 419 symptoms [43]. Nevertheless, studies of striatal pathology have reported inconsistent 420 differences between patients and controls [6]. The variability of the striatum is greater in 421 patients than in controls, which relates to overall structural morphometry [27], dopamine 422 D2 receptor and transporter levels [44]. This indicates that differences might exist within 423 subgroups of the disorder [6]. In addition, it is still uncertain whether the discrepancy in 424 striatum between cases and controls indicates a primary pathology or an effect of 425 antipsychotic treatment [6]. Interestingly, this study's subtype-specific striatal differences 426 were replicated in a subset of individuals who had not received antipsychotic treatment, 427 suggesting that striatal variability persists even in those without antipsychotic treatment. In 428 addition, a recent study reveals a more pronounced and widespread pattern of thinner 429 cortex in deficit schizophrenia, a clinically defined subtype with primary, enduring negative 430 symptoms, compared to non-deficit schizophrenia [45]. This also suggests the existence 431 of distinct subtypes distinguished by unique neuroimaging features. Taken together, our 432 neurostructural subtyping differentiated subgroups with unique pathological features, 433 thereby enhancing our understanding of the neurobiological mechanisms underlying 434 schizophrenia.

435 The two newly identified subtypes may have several potential therapeutic implications. 436 While the underlying mechanisms associated with a subtype-specific symptomatic 437 trajectory remain unclear, our research shows divergent long-term clinical outcomes 438 between the two neurostructural subtypes. As the disease advanced, for subtype 1, the 439 negative and depression/anxiety symptoms gradually worsened; for subtype 2 these 440 symptoms remained stable. In addition, subtype1 experienced worse positive symptoms 441 than subtype 2 at the late stage of disease (i.e., duration > 10 years). This is consistent 442 with a prior study that reported greater gray matter reduction in frontal regions in treatment-443 resistant compared with treatment-responsive individuals with schizophrenia [46]. Another 444 intriguing aspect is that our prior research on treatment-resistant schizophrenia 445 demonstrated that electroconvulsive therapy (ECT) can substantially enhance the volume 446 of the hippocampus and insula; this is also associated with psychotic symptom alleviation 447 [47-49]. Notably, these two brain regions were also identified as the 'origins' of gray matter

loss separately in each subtype. This observation raises the possibility of exploring
neuromodulation interventions, such as transcranial magnetic stimulation (TMS), to target
these specific brain regions.

451 This study has several limitations. First, while the SuStaIn algorithm estimates 452pathophysiological trajectories from cross-sectional MRI data, it remains crucial to validate 453 these outcomes with longitudinal data to verify the brain changes with disease progression 454 over time. Second, the current study benefits from a large sample size, but the inclusion of 455 data from various sites could potentially be influenced by confounding factors, including 456 diverse cohorts, scanners, and locations. Harmonization methods have been employed to 457 alleviate disparities across MRI acquisition protocols. Nonetheless, it remains essential to 458 collect a sufficiently large sample from multi-centers under a standard imaging protocol 459 and experimental paradigm. Third, a substantial portion of individuals with schizophrenia 460 were likely to have received or currently use medications, and data from medication-461 naïve/free individuals were only available for a subset of the datasets. One important 462 limitation is the assumption of progressive pathology in schizophrenia (discrete events of 463 tissue loss or continuous downward drift), when applying SuStaln. The few existing very 464 long-term imaging studies in schizophrenia support this stance [50] but selection bias 465 cannot be fully overcome in the recruitment process for neuroimaging studies. Routine 466 anatomical MRI for every person with psychosis seeking help, with periodic repeats, may 467 provide better view of the validity of progressive pathology in the future.

468 In summary, our study reveals two distinct neurostructural schizophrenia subtypes 469 based on patterns of pathological progression of gray matter loss. We extend the 470 reproducibility and generalisability of these brain imaging-based subtypes across illness 471 stages, medication treatments and different sample locations worldwide, independent of 472 macroeconomic and ethnic factors that differed across these sites. The identified subtypes 473 exhibit distinct signatures of neuroanatomical pathology and psychotic symptomatic 474 trajectories, highlighting the heterogeneity of the neurobiological changes associated with 475 disease progress. This new imaging-based taxonomy shows potential for identification of 476 homogeneous subsamples of individuals with shared neurobiological characteristics. This 477 may be a first crucial step in the transition from only syndrome-based to both syndrome-478 and biology-based identification of mental disorder subtypes in the near future.

## 479 **4. Methods**

#### 480 **4.1 Study samples**

481 This study analyzed cross-sectional T1-weighted structural MRI data from a total of 482 4,291 individuals diagnosed with schizophrenia (1,709 females, mean age= $32.5\pm11.9$ 483 years) and 7,078 healthy controls (3,461 females, mean age= $33.0\pm12.7$  years). These 484 datasets came from 21 cohorts of ENIGMA schizophrenia working groups from various 485 countries around the world, 11 cohorts collected from Chinese hospitals over the last ~10 years, and 9 cohorts from publicly available datasets, i.e., HCP-EP [51], JP-SRPBS [52], 486 487 fBIRN [53], MCIC [54], NMorphCH [55], NUSDAST [56], DS000030 [57], DS000115 [58] 488 and DS004302 [59]. The datasets came from various countries around the world 489 (Extended Data Fig.5). Details of demographics, geographic location, clinical 490 characteristics, and inclusion/exclusion criteria for each cohort may be found in the 491 Supplementary Information (Supplementary Table S1-2).

The severity of symptoms was evaluated by the Positive and Negative Syndrome Scale (PANSS) [60], including a positive scale (total score of P1-P7), a negative scale (total score of N1-N7), a general psychopathology scale (total score of G1-G16) and total score. In addition, phenotypic characteristics were further quantified in three dimensions, such as cognitive (total score of P2, N5, G5, G10, G11), depression/anxiety (total score of G1, G2, G3, G6, G15) and excitement (total score of P4, P7, G44, G14) via a five-factor model of schizophrenia [61].

All sites obtained approval from their local institutional review boards or ethics committees, and written informed consent from all participants and/or their legal guardians. The present study was carried out under the approve from the Medical Research Ethics Committees of Fudan University (Number: FE222711).

503

#### **4.2 Image acquisition, processing and quality control**

505 T1-weighted structural brain MRI scans were acquired at each study site. We used a 506 standardized protocol for image processing using the ENIGMA Computational Anatomy 507 Toolbox (CAT12) across multiple cohorts (<u>https://neuro-jena.github.io/enigma-cat12/</u>). 508 These protocols enable region-based gray matter volume (GMV) measures for image data 509 based on the automated anatomical (AAL3) atlas [62]. Further details of image acquisition 510 parameters and quality control may be found in **Supplementary Information** 511 (**Supplementary Table S1-2**).

512

#### 513 **4.3 Data harmonization**

The ROI-wise GMV measures were first adjusted by regressing out the effects of sex, age, the square of age, site and total intracranial volume (TIV) using a regression model [22]. Subsequently, a harmonization procedure was performed using the ComBat algorithm for correcting multi-site data [63]. The adjusted values were transformed as z-scores (i.e., normative deviations) relative to the healthy control group. We multiplied these z-scores by -1 so that the z-score increases as regional GMV decreases. Finally, we removed these samples if they were marked as a statistical outlier (>5 standard deviations away from the

521 global mean). After the quality control, 11,260 individuals were included, of which 4,222 522 were schizophrenia patients (1,683 females, mean age= $32.4 \pm 12.4$  years) and 7,038 523 healthy subjects (3,440 females, mean age= $33.0 \pm 12.4$  years).

524

### 525 **4.4 Disease progress modelling**

526 To uncover diverse patterns of pathophysiological progression from cross-sectional 527 only MRI data and cluster individuals into groups (subtypes), we employed a novel 528 machine learning approach - Subtype and Stage Inference (SuStaIn) [19]. The 529 methodology of SuStaln has been described in detail previously [19]. Here, we briefly 530 describe the main parameter choices specific to the current study. The SuStaln model 531 requires an M x N matrix as input. M represents the number of cases (M=4,222). N is the 532 number of biomarkers (N=17). 17 gray matter biomarkers that were previously used for 533 SuStaln modelling in schizophrenia [22]. Here, all of the AAL3 regions of whole brain were 534 separated and merged into 17 regions of interest (ROIs) [22], including frontal lobe, 535 temporal lobe, parietal lobe, occipital lobe, insula, cingulate, sensorimotor, Broca's area, 536 cerebellum, hippocampus, parahippocampus, amygdala, caudate, putamen, pallidum, 537 accumbens and thalamus (Supplementary Table S6). We then ran the SuStaIn algorithm 538 with 25 start points and 100,000 Markov Chain Monte Carlo (MCMC) iterations [19] to 539 estimate the most likely sequence that describes spatiotemporal pattern of 540 pathophysiological progression (i.e., 'trajectory').

541 SuStaIn can identify diverse trajectories of pathophysiological progression given a 542 subtype number K. We fitted the model for K=2-6 subtypes ('trajectories'), separately. The 543 optimal number of subtypes was determined according to the reproducibility of individual 544 subtyping via a two-fold cross-validation procedure, as described previously [22]. 545 Specifically, all individuals were randomly split into two non-overlapping folds. For each 546 fold, we trained the SuStaIn model. For each individual, the trained SuStaIn model provides 547 a subtype label. We measured the consistency of the subtype labeling across all individuals 548 between two folds by using the Dice coefficient. This above procedure was repeated ten 549 times. The largest Dice coefficient was obtained for K=2 (see Figure 1a), indicating the 550 best consistency based on cross-validation. Finally, the two-cluster model of SuStaIn was 551fitted to the entire sample. The most probable sequence (i.e., the order of biomarkers) was 552 evaluated for each 'trajectory' via SuStaIn. For each individual, SuStaIn calculated the 553 probability (ranging from 0 to 1) of belonging to each 'trajectory', and assigned the 554individual into a sub-stage of the maximum likelihood 'trajectory' through MCMC iterations. 555 We also estimated the SuStaIn 'trajectories' based on a subsample from individuals with 556first-episode schizophrenia whose illness duration was less than two years (N=1,122, 513 557 females, mean age= $25.4\pm8.6$  years), and a subsample of medication-naïve individuals 558 with schizophrenia (N=718, 353 females, mean age= $23.7\pm7.8$  years).

559

#### 560 **4.5 Visualization of pathophysiological progression trajectory**

561 To visualize the spatiotemporal patterns of pathophysiological progression, we 562 calculated the mean z-score of regional GMV across individuals belonging to the same 563 substage of each SuStaln 'trajectory'. The images of ROI-wise GMV z-scores were

564mapped into a glass brain template via visualization tools implemented in ENIGMA Toolbox565(https://enigma-toolbox.readthedocs.io/en/latest/index.html)andBrainNetViewer566(https://www.nitrc.org/projects/bnv/).

To examine whether the SuStaIn stage (a continuous indicator of the 'temporal' stage of SuStaIn 'trajectory') is associated with pathological processes and clinical characteristics in schizophrenia, we performed Spearman correlations between the SuStaIn stages and the degree of brain atrophy (i.e., regional GMV) in schizophrenia. We also examined whether SuStaIn stages were linked to disease duration, severity of symptoms, and phenotypic characteristics.

573

#### 574 **4.6** Neuroanatomical signatures using regional morphological measures

575 To further characterize the neuroanatomical signatures associated with each subtype, 576 we conducted regional morphological analyses in a subsample including 1,840 individuals 577 with schizophrenia and 1,780 healthy controls. Brain morphological measures, such as 578 cortical thickness, cortical surface area, cortical volume and subcortical volume, were 579 quantified using FreeSurfer (version 7.3, http://surfer.nmr.mgh.harvard.edu/). A total of 580 68x3 regional measures for cortical thickness, cortical surface area and cortical volume 581 were extracted based on the DK atlas [64], along with 14 subcortical regions (bilaterally 582 nucleus accumbens, amygdala, caudate, hippocampus, pallidum, putamen and thalamus) 583 and 2 lateral ventricles. In addition, we performed an automated subregion segmentation 584 (https://surfer.nmr.mgh.harvard.edu/fswiki/SubregionSegmentation) for the hippocampal 585 substructures (n=38 subregions) [65], the nuclei of the amygdala (n=18) [66], the thalamic 586 nuclei (n=50) [67], and the brain stem structures (n=4) [68], yielding a total of 110 587 subregional volumetric measures.

588 Regional morphological measures for each individual with schizophrenia were 589 adjusted by regressing out the effects of sex, age, the square of age, TIV and site, and 590 then transformed to z-scores (i.e., normative deviations from healthy control group). The 591 mean regional morphological z-score across individuals belonging to each subtype was 592 calculated, and mapped to brain templates for visualization of neuroanatomical signature 593 deviation for each subtype relative to healthy population. To further manifest subtype-594specific signature in neuroanatomical pathology, we compared the regional morphological 595 z-scores between the two subtypes using two sample t-tests. Multiple comparisons were 596 corrected by family wise error (FWE) correction.

597

#### 598 **4.7 Distinct symptom profiles between subtypes**

To characterize the psychotic symptomatic trajectory with disease duration increases for each subtype, we further divided the individuals of each subtype into three subgroups according to their illness durations (early stage: <2 years; middle stage: 2-10 years; late stage: >10 years). We compared the difference of symptoms among the three stages of disease in each subtype using ANOVA. Two sample *t*-tests were performed to compare the inter-subtype differences separately between each of the stages.

## 605 **Data availability**

606 Data of NMorphCH, FBIRN and NUSDAST were obtained from the SchizConnect, a 607 publicly available website (http://www.schizconnect.org/documentation#by project). The 608 NMorphCH dataset and NUSDAST dataset were download through a query interface at 609 the SchizConnect (http://www.schizconnect.org/queries/new). The FBIRN dataset was 610 download from https://www.nitrc.org/projects/fbirn/. The DS000115 dataset was download 611 from OpenfMRI database (https://www.openfmri.org/). The DS000030 dataset was 612 available at https://legacy.openfmri.org/dataset/ds000030/. The DS004302 dataset was 613 available at https://openneuro.org/datasets/ds004302/versions/1.0.1. The HCP-EP 614 dataset was available at https://www.humanconnectome.org/study/human-connectome-615 project-for-early-psychosis/. The Japanese SRPBS Multi-disorder MRI Dataset was 616 available at https://bicr-resource.atr.jp/srpbsopen/. Requests for ENIGMA data can be 617 applied via the ENIGMA Schizophrenia Working Group 618 (https://enigma.ini.usc.edu/ongoing/enigma-schizophrenia-working-group/). Requests for 619 raw and analyzed data can be made to the corresponding author (J.Feng, 620 jffeng@fudan.edu.cn) and will be promptly reviewed by the Fudan University Ethics 621 Committee to verify whether the request is subject to any intellectual property or 622 confidentiality obligations.

623

## 624 **Code availability**

625 SuStaIn algorithm is available on the UCL-POND GitHub (https://github.com/ucl-626 pond/). T1-weighted images were processed using the Computational Anatomy Toolbox 627 for Standardized Processing of ENIGMA Data (https://neuro-jena.github.io/enigma-cat12/). 628 А protocol for the current data processing is available at 629 https://docs.google.com/document/d/1lb9v0v4j OrgAKDh6 9fl3Hz2Wcfg46c/edit/. 630 FreeSurfer (version 7.3, http://surfer.nmr.mgh.harvard.edu/) was used to quantify various 631 morphological measures, such as cortical thickness, cortical surface area, cortical volume 632 and subcortical volume. The visualization of ROI-wise z-score images was conducted 633 using BrainNetViewer (https://www.nitrc.org/projects/bnv/).

634

## 635 Acknowledgements

636 This work was supported by the grant from Science and Technology Innovation 2030-637 Brain Science and Brain-Inspired Intelligence Project (No. 2022ZD0212800). This work 638 was supported by National Natural Science Foundation of China (No. 82202242, 639 82071997). This work was supported by the projects from China Postdoctoral Science 640 Foundation (No. BX2021078, 2021M700852). This work was supported by the Shanghai 641 Rising-Star Program (No. 21QA1408700) and the Shanghai Sailing Program 642 (22YF1402800) from Shanghai Science and Technology Committee. This work was 643 supported by National Key R&D Program of China (No. 2019YFA0709502), the grant from 644 Shanghai Municipal Science and Technology Major Project (No. 2018SHZDZX01), ZJ Lab,

645 and Shanghai Center for Brain Science and Brain-Inspired Technology, and the grant from 646 the 111 Project (No. B18015). ASRB: Supported by NHMRC Project Grants (630471 & 647 1081603). ESO: Supported by Ministry of Health of the Czech Republic, grants nr. NU21-648 08-00432 and NU20-04-00393. Supported by Ministry of Health, Czech Republic - DRO 649 2021 ("Institute for Clinical and Experimental Medicine - IKEM, IN: 00023001"). FOR2107: 650 Funded by the German Research Foundation (Deutsche Forschungsgemeinschaft DFG; 651 Forschungsgruppe/Research Unit FOR2107). Principal investigators (PIs) with respective 652 areas of responsibility in the FOR2107 consortium are: Work Package WP1, 653 FOR2107/MACS cohort and brainimaging: Tilo Kircher (speaker FOR2107; DFG grant 654 numbers KI588/14-1, KI588/14-2, KI588/20-1, KI588/22-1), Udo Dannlowski (co-speaker 655 FOR2107; DA 1151/5-1, DA 1151/5-2, DA1151/6-1), Axel Krug (KR 3822/5-1, KR 3822/7-656 2), Igor Nenadic (NE2254/1-2, NE2254/3-1, NE2254/4-1, NE2254/2-1), Carsten Konrad (KO 4291/3-1). IMH: Supported by research grants from the National Healthcare Group, 657 658 Singapore (SIG/05004; SIG/05028), and the Singapore Bioimaging Consortium (RP 659 C009/2006) research grants awarded to Kang Sim. JBUN: Supported by Korean Mental 660 Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea 661 (HL19C0015) and a grant of the Korea Health Technology R&D Project through the Korea 662 Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, 663 Republic of Korea (HR18C0016). OLIN: Supported by MH106324. Osaka: Supported by 664 JSPS KAKENHI (Grant Number JP21K12153), ABiS (JSPS KAKENHI Grant Number 665 JP22H04926), Brain/MINDS & beyond studies (Grant Number JP18dm0307002) from the AMED. PENS: Supported by department of Veterans Affairs CSR&D (I01CX000227) and 666 667 National Institutes of Health (U01MH108150) to Scott R. Sponheim. RomeSL: Supported 668 by Italian Ministry of Health, grant Ricerca Corrente RC 23, RF-2019-12370182. SoCAT: 669 Supported by THE SCIENTIFIC AND TECHNOLOGICAL RESEARCH COUNCIL OF 670 TÜRKİYE. SWIFT: Supported by a NARSAD grant from the Brain & Behavior Research 671 Foundation (28445) and by a Research Grant from the Novartis Foundation (20A058). 672 UCISZ: Supported by the National Institute of Mental Health of the National Institutes of 673 Health under award number R21MH097196. UNINA: Supported by 674 #NEXTGENERATIONEU (NGEU) and funded by the Ministry of University and Research 675 (MUR), National Recovery and Resilience Plan (NRRP), project MNESYS (PE0000006) -676 A Multiscale integrated approach to the study of the nervous system in health and disease 677 11.10.2022). COBRE: Supported by NIMH: 5R01MH094524-1; (DN. 1553 678 3R01MH121246; 1P20RR021938. TOPSY: Supported by the Canada First Research 679 Excellence Fund, awarded to the Healthy Brains, Healthy Lives initiative at McGill 680 University (through a New Investigator Supplement) and the Monique H. Bourgeois Chair 681 in Developmental Disorders. He receives a salary award from the Fonds de recherche du 682 Québec - Santé (FRQS). OSLO: Supported by The Research Council of Norway (249795, 683 300767), the South-Eastern Norway Regional Health Authority (2014097, 2019101), KG 684 Jebsen Stiftelsen, the European Research Council under the European Union s Horizon 685 2020 research and Innovation program (802998), and the European Union-funded Horizon 686 Europe project 'environMENTAL' (no. 101057429). HCP-EP: Research using Human 687 Connectome Project for Early Psychosis (HCP-EP) data reported in this publication was 688 supported by the National Institute of Mental Health of the National Institutes of Health

689 under Award Number U01MH109977. JP-SRPBS: Data used in the preparation of this 690 work were obtained from the DecNef Project Brain Data Repository (https://bicr-691 resource.atr.jp/srpbsopen/) gathered by a consortium as part of the Japanese Strategic 692 Research Program for the Promotion of Brain Science (SRPBS) supported by the 693 Japanese Advanced Research and Development Programs for Medical Innovation 694 (AMED). FBIRN: Data used for this study were downloaded from the FunctionBIRN Data 695 Repository, supported by grants to the Function BIRN (U24-RR021992) Testbed funded by 696 theNational Center for Research Resources at the National Institutes of Health, U.S.A. 697 MCIC: The imaging data and demographic information was collected and shared by 698 [University of Iowa, University of Minnesota, University of New Mexico, Massachusetts 699 General Hospital the Mind Research Network supported by the Department of Energy 700 under Award Number DE-FG02-08ER64581. NMorphCH: Data collection and sharing was 701 funded by NIMH grant R01 MH056584. NUSDAST: Data collection and sharing was funded 702 by NIMH grant 1R01 MH084803. This work is supported by the Zhangjiang International 703 Brain Biobank (ZIB) Consortium.

704

## 705 Competing Interests Statement

706 Lena Palaniyappan reports personal fees from Janssen Canada, Otsuka Canada, 707 SPMM Course Limited UK and the Canadian Psychiatric Association; book royalties from 708 Oxford University Press; and investigator-initiated educational grants from Sunovion, 709 Janssen Canada and Otsuka Canada, outside the submitted work. Tilo Kircher received 710 unrestricted educational grants from Servier, Janssen, Recordati, Aristo, Otsuka, 711 neuraxpharm. Philipp Homan has received grants and honoraria from Novartis, Lundbeck, 712 Mepha, Janssen, Boehringer Ingelheim, Neurolite outside of this work. Ole A. Andreassen 713 is a consultant to Cortechs.ai and received speakers honorarium from Lundbeck, Janssen, 714 Sunovion. These interests played no role in the research reported here. Other authors 715 disclose no conflict of interest.

	HC(n=7,038)		SCZ(n=4	SCZ(n=4,222)		SCZ subtype1(n=2,622)		e2(n=1,600)
	n	mean(SD)	n	mean(SD)	n	mean(SD)	n	mean(SD)
Sex (Female/Male)	3440/3598	-	1683/2539	-	1044/1578	-	639/961	-
Age (years)	7038	<b>33.0(12.6</b> )	4222	32.4(11.9)	2622	32.4(11.8)	1600	32.4(12.0)
Illness duration (years)	-	-	2333	10.5(10.4)	1442	10.4(10.5)	891	10.5(10.4)
FES/Chronic/Unknown	-	-	1112/1623/1477	-	696/1002/924	-	426/621/553	-
PANSS Positive scale (P1-P7)	-	-	2651	17.2(6.8)	1622	17.3(3.9)	1029	17.0(6.7)
PANSS Negative scale (N1-N7)	-	-	2651	17.5(7.6)	1622	17.6(7.6)	1029	17.3(7.6)
PANSS General scale (G1-G16)	-	-	2651	34.8(11.6)	1622	35.2(11.6)	1029	34.3(11.6)
PANSS Total score	-	-	2651	69.5(22.4)	1622	70.0(22.4)	1029	68.6(22.5)
PANSS excitement dimension (P4, P7, G44, G14)	-	-	1322	8.2(3.5)	823	8.2(3.4)	499	8.2(3.5)
PANSS depression/anxiety dimension (G1, G2, G3, G6, G15)	-	-	1322	11.3(4.1)	823	11.4(4.1)	499	11.1(4.2)
PANSS cognitive dimension (P2, N5, G5, G10, G11)	-	-	1322	10.6(4.0)	823	10.5(4.0)	499	10.6(4.0)

Table 1. Demographic and clinical characteristics in	the primary s	sample including 4	.222 schizophrenia	patients and 7.038 healthy	v controls.

Abbreviation: HC, healthy control; SCZ, schizophrenia; FES, first-episode schizophrenia; PANSS, Positive and Negative Syndrome Scale.

717

Morphometry measures	Subtype-specific neuroanatomical signatures
Cortical Thickness/Volume/Area	a) Both subtype1 and subtype2 exhibit a moderate degree in the average cortical thickness reduction.
	b) Reduction of average cortical volume/area is only observed in the subtype1.
	c) The worst reduction of cortical thickness/volume/area is located within the superior frontal regions for the subtype1, but in the superior/medial temporal
	regions for the subtype2.
Subcortical Volume	a) Enlargement of lateral ventricle is found in both subtype1 and subtype2, but much larger in the subtype2.
	b) Worse loss volumes of hippocampus, amygdala, thalamus and accumubens are observed in the subtype2, compared to the subtype1.
	c) Volumes of striatum (i.e., caudate, putamen) are increased in the subtype1, but decreased in the subtype2, compared to the healthy population.
Hippocampus segmentation	a) Volume loss in hippocampal subregions is worse in the subtype2, compared to the subtype1.
	b) The most significant volume loss is in the molecular layer for the subtype2.
Amygdala segmentation	a) The subtype2 shows worse volume loss in amygdala subregions, compared to the subtype1.
	b) The most significant decrease in volume is in the cortico-amygdaloid transition area for both the subtypes.
Thalamus segmentation	a) The subtype2 shows worse volume loss in thalamus subregions, compared to the subtype1.
Brain stem segmentation	a) Volume loss of brain stem subregions is only observed in the subtype2.

#### Table 2. Main findings of subtype-specific neuroanatomical signatures.

719

Symptoms	Subtype 1			F test		Subtype 2			F test	
	Early	Middle	Late	F		Early	Middle	Late	F	
	(n=579)	(n=362)	(n=400)	F	Р	(n=371)	(n=216)	(n=282)	F	Р
PANSS Positive scale (P1-P7)	19.5(6.4)	16.0(6.7)	16.7(7.0)*	37.4	1.60E-16	19.6(6.4)	16.0(6.7)	15.2(6.2)*	41.9	4.68E-18
PANSS Negative scale (N1-N7)	16.8(7.3)	17.4(7.4)	18.3(7.7)	4.6	9.98E-03	17.3(7.4)	17.1(7.5)	17.4(7.5)	0.1	0.884
PANSS General scale (G1-G16)	37.6(10.0)	34.1(12.2)	35.3(13.3)*	10.6	2.80E-05	37.7(10.8)	33.7(12.4)	32.7(12.0)*	15.6	2.30E-07
PANSS Total score	73.9(19.7)	67.5(23.2)	70.2(25.0)*	9.3	9.40E-05	74.5(20.9)	66.7(23.4)	65.4(22.4)*	15.7	2.05E-07
PANSS excitement dimension (P4, P7,		7.0(0,0)		4.0	0.045.00		7 0/0 1)	7.0(0.7)	4.40	0.047
G44, G14)	8.8(3.4)	7.9(3.3)	8.2(3.4)	4.9	8.01E-03	8.7(3.3)	7.8(3.4)	7.8(3.7)	4.12	0.017
PANSS depression/anxiety dimension		44 7(4 0)		5.0	0.005.00			44.0/4.0)*		0.544
(G1, G2, G3, G6, G15)	11.2(3.7)	11.7(4.2)	12.5(4.9)*	5.9	2.86E-03	11.4(4.0)	10.8(4.4)	11.3(4.9)*	0.7	0.511
PANSS cognitive dimension (P2, N5,	40 4 (0 7)	40.0(4.0)	40.0(4.0)	40.5		40.0/0.0)	40.0(0.0)	44 4/4 7)	0.0	0.004
G5, G10, G11)	10.1(3.7)	10.8(4.0)	12.0(4.6)	13.5	1.74E-06	10.3(3.8)	10.9(3.9)	11.4(4.7)	2.8	0.061

Table 3. Symptom scores for each subtype at different stages of disease duration.

<sup>\*</sup> indicates significant difference between the subtype1 and subtype2 using two sample t test (p<0.05).

## 721 Figures Legend

722 Figure 1. Two pathophysiological progression trajectories in schizophrenia. (a) Dice coefficient 723 indicates that K=2 is the optimal number of subtypes with best consistency of the subtype labeling 724 between two independent schizophrenia populations using non-overlap 2-folds cross-validation 725 procedure. Data are presented as mean values +/- SD. (b) The proportion of individuals whose subtype 726 labels keep consistent by non-overlap cross-validation procedure. (c) Sequences of regional volume 727 loss across seventeen brain regions for each 'trajectory' via SuStaIn are shown in y-axis. The heatmap 728 shows regional volume loss in which biomarker (y-axis) in a particular 'temporal' stage (T0-T16) in the 729 trajectory (x-axis). The Color bar represents the degree of grav matter volume (GMV) loss in 730 schizophrenia relative to healthy controls (i.e., z score). (d) Spatiotemporal pattern of pathophysiological 731 'trajectory'. The z-score images are mapped to a glass brain template for visualization. Spatiotemporal 732 pattern of gray matter loss displays a progressive pattern of spatial extension along with later 'temporal' 733 stages of pathological progression, that is distinct between trajectories. (e-f) Pathological stages of 734 SuStain are correlated with reduced gray matter volume of Broca's area and hippocampus. (g-i) 735 Pathological stages of SuStaIn are correlated with longer disease duration, worse negative symptoms 736 and worse cognitive symptoms. 737 Figure 2. Trajectories are reproducibility for samples from different locations of the world. Two 738 sets of 'trajectories' are separately derived from two non-overlapping location cohorts, that are (a) East 739 Asian ancestry (EAS) cohort, and (b) European ancestry (EUR) cohort. The Color bar represents the 740 degree of gray matter volume (GMV) loss in schizophrenia relative to healthy controls (i.e., z score). (c) 741 The similarity of the spatiotemporal pattern of each 'trajectory' between any two of cohorts is shown by 742 the heatmap. The color bar of the heatmap represents the similarity, which is quantified via the 743 Spearman correlation coefficient between the trajectories from two cohorts. A total of six location cohorts 744 are classified by where the sample locate at, including the EAS, EUR, China, Japan, Europe and North 745 America. The whole sample is labelled as a cross-ancestry cohort. 746 Figure 3. Subtype-specific signatures in neuroanatomical pathology. Regional Morphological z-747 scores (i.e., normative deviations from healthy control group) for each subtype are mapped to a brain 748 template for visualization. Effect size of inter-subtype difference is quantified using Cohen's d. 749 Figure 4. Symptomatic trajectories across three stages of disease duration. Individuals of each 750 subtype are divided into three subgroups according to their illness durations (early stage:  $\leq 2$  years; 751 middle stage: 2-10 years; late stage: >10 years). Data are presented as mean values +/- se. \* p<0.05. 752 Extend Data Fig 1. Pathophysiological progression trajectories in first-episode population and 753 medication-naïve population. Trajectories are repeated based on the subsample data from the first-754 episode schizophrenia patients whose illness duration was less than two years (N=1,112, 513 females, 755mean age=25.4 ± 12.4 years), and another subsample data from medication-naïve patients with 756 schizophrenia (N=718, 353 females, mean age=23.7±12.1 years). 757 Extend Data Fig 2. Comparisons of morphological z-score between the two subtypes. A larger

positive z-score indicates a larger deviation of reduction relative to healthy control group. Two sample t

- test is conducted to examine inter-subtype difference for the (a) averaged cortical volume (t=9.36,
- 760 p<10e-16, Cohen's d=0.446); (b) averaged cortical area (t=8.09, p<10e-16, Cohen's d=0.386); (c)

- averaged cortical thickness (t=1.29, p=0.198, Cohen's d=0.061); (d) thalamus volume (t=-4.28, p=1.97e-
- 762 5, Cohen's d=-0.205); (e) brain stem volume (t=-9.79, p<10e-16, Cohen's d=-0.469); (f) hippocampus
- 763 volume (t=-9.25, p<10e-16, Cohen's d=-0.449); (g) amgydala volume (t=-7.83, p=8.44e-15, Cohen's d=-
- 764 0.379); (h) accumbens volume (t=-6.40, p=1.94e-10, Cohen's d=-0.305); (i) caudate volume (t=-9.82,
- 765 p<10e-16, Cohen's d=-0.468); (j) putamen volume (t=-8.14, p<10e-16, Cohen's d=-0.389).
- 766 Extend Data Fig 3. Hippocampus subregional morphological z-score for the two subtypes. A
- 767 larger positive z-score indicates a larger deviation of reduction relative to healthy control group.
- 768 Extend Data Fig 4. Amygdala subregional morphological z-score for the two subtypes. A larger
- positive z-score indicates a larger deviation of reduction relative to healthy control group.
- 770 Extend Data Fig 5. Geographic map of included datasets.

## 771 References

772	1.	The, L., <i>ICD-11: a brave attempt at classifying a new world.</i> The Lancet, 2018.
773		<b>391</b> (10139) : p. 2476.
774	2.	Oren, O., B.J. Gersh, and D.L. Bhatt, Artificial intelligence in medical
775		imaging: switching from radiographic pathological data to clinically
776		<i>meaningful endpoints.</i> Lancet Digit Health, 2020. <b>2</b> (9): p. e486-e488.
777	3.	Rajpurkar, P., et al., <i>AI in health and medicine.</i> Nat Med, 2022. <b>28</b> (1): p.
778		31-38.
779	4.	Organization, W.H., The global burden of disease: 2004 update. 2008: World
780		Health Organization.
781	5.	Howes, O. D. and E. C. Onwordi, <i>The synaptic hypothesis of schizophrenia version</i>
782		<i>III: a master mechanism.</i> Mol Psychiatry, 2023.
783	6.	McCutcheon, R.A., J.H. Krystal, and O.D. Howes, Dopamine and glutamate in
784		schizophrenia: biology, symptoms and treatment. World Psychiatry, 2020. 19(1):
785		p. 15-33.
786	7.	Wolfers, T., et al., Mapping the Heterogeneous Phenotype of Schizophrenia and
787		Bipolar Disorder Using Normative Models. JAMA Psychiatry, 2018. 75(11): p.
788		1146-1155.
789	8.	Fusar-Poli, P., et al., <i>Heterogeneity of Psychosis Risk Within Individuals</i>
790		at Clinical High Risk: A Meta-analytical Stratification. JAMA Psychiatry,
791		2016. <b>73</b> (2): p. 113–20.
792	9.	McCutcheon, R.A., et al., <i>The efficacy and heterogeneity of antipsychotic</i>
793		response in schizophrenia: A meta-analysis. Mol Psychiatry, 2021. <b>26</b> (4): p.
794		1310-1320.
795	10.	Collado-Torres, L., et al., <i>Regional Heterogeneity in Gene Expression</i> ,
796	10.	Regulation, and Coherence in the Frontal Cortex and Hippocampus across
797		Development and Schizophrenia. Neuron, 2019. <b>103</b> (2): p. 203–216 e8.
798	11.	Brugger, S.P. and O.D. Howes, <i>Heterogeneity and Homogeneity of Regional Brain</i>
799	11.	Structure in Schizophrenia: A Meta-analysis. JAMA Psychiatry, 2017. 74(11):
800		p. 1104-1111.
801	12.	Braff, D.L., et al., Lack of use in the literature from the last 20 years
802	12.	
		supports dropping traditional schizophrenia subtypes from DSM-5 and ICD-11.
803	1.0	Schizophr Bull, 2013. <b>39</b> (4): p. 751–3.
804	13.	Wen, J., et al., <i>Multi-scale semi-supervised clustering of brain images:</i>
805	1.4	Deriving disease subtypes. Med Image Anal, 2022. <b>75</b> : p. 102304.
806	14.	Lalousis, P.A., et al., <i>Heterogeneity and Classification of Recent Onset</i>
807		Psychosis and Depression: A Multimodal Machine Learning Approach. Schizophr
808		Bull, 2021. <b>47</b> (4): p. 1130–1140.
809	15.	Chand, G.B., et al., <i>Two distinct neuroanatomical subtypes of schizophrenia</i>
810		<i>revealed using machine learning.</i> Brain, 2020. <b>143</b> (3): p. 1027-1038.
811	16.	Yang, Z., et al., A deep learning framework identifies dimensional
812		representations of Alzheimer's Disease from brain structure. Nat Commun, 2021.
813		<b>12</b> (1): p. 7065.

814	17.	Dwyer, D.B., et al., Brain Subtyping Enhances The Neuroanatomical
815		Discrimination of Schizophrenia. Schizophr Bull, 2018. 44(5): p. 1060-1069.
816	18.	Luo, C., et al., Subtypes of schizophrenia identified by multi-omic measures
817		associated with dysregulated immune function. Mol Psychiatry, 2021. <b>26</b> (11):
818		p. 6926–6936.
819	19.	Young, A.L., et al., Uncovering the heterogeneity and temporal complexity of
820		neurodegenerative diseases with Subtype and Stage Inference. Nat Commun, 2018.
821		<b>9</b> (1): p. 4273.
822	20.	Vogel, J.W., et al., Four distinct trajectories of tau deposition identified
823		<i>in Alzheimer's disease.</i> Nat Med, 2021. <b>27</b> (5): p. 871-881.
824	21.	Young, A.L., et al., Characterizing the Clinical Features and Atrophy Patterns
825		of MAPT-Related Frontotemporal Dementia With Disease Progression Modeling.
826		Neurology, 2021. <b>97</b> (9): p. e941-e952.
827	22.	Jiang, Y., et al., Neuroimaging biomarkers define neurophysiological subtypes
828		with distinct trajectories in schizophrenia. Nature Mental Health, 2023. $1(3)$ :
829		p. 186–199.
830	23.	van Erp, T.G.M., et al., Cortical Brain Abnormalities in 4474 Individuals
831		With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging
832		Genetics Through Meta Analysis (ENIGMA) Consortium. Biol Psychiatry, 2018.
833		<b>84</b> (9): p. 644–654.
834	24.	van Erp, T.G., et al., Subcortical brain volume abnormalities in 2028
835		individuals with schizophrenia and 2540 healthy controls via the ENIGMA
836		<i>consortium.</i> Mol Psychiatry, 2016. <b>21</b> (4): p. 585.
837	25.	Okada, N., et al., Subcortical volumetric alterations in four major
838		psychiatric disorders: a mega-analysis study of 5604 subjects and a volumetric
839		data-driven approach for classification. Mol Psychiatry, 2023.
840	26.	Koshiyama, D., et al., White matter microstructural alterations across four
841		<i>major psychiatric disorders: mega-analysis study in 2937 individuals.</i> Mol
842		Psychiatry, 2020. <b>25</b> (4): p. 883-895.
843	27.	Howes, O.D., et al., Neuroimaging in schizophrenia: an overview of findings
844		and their implications for synaptic changes. Neuropsychopharmacology, 2023.
845		<b>48</b> (1): p. 151–167.
846	28.	Alnaes, D., et al., Brain Heterogeneity in Schizophrenia and Its Association
847		<i>With Polygenic Risk.</i> JAMA Psychiatry, 2019. <b>76</b> (7): p. 739-748.
848	29.	Howes, O. D. and S. Kapur, A neurobiological hypothesis for the classification
849		of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic).
850		Br J Psychiatry, 2014. <b>205</b> (1): p. 1–3.
851	30.	Jiang, Y., et al., Progressive Reduction in Gray Matter in Patients with
852	000	Schizophrenia Assessed with MR Imaging by Using Causal Network Analysis.
853		Radiology, 2018. <b>287</b> (2): p. 729.
854	31.	Kirschner, M., et al., Orbitofrontal-Striatal Structural Alterations Linked
855	01.	to Negative Symptoms at Different Stages of the Schizophrenia Spectrum.
855 856		Schizophr Bull, 2021. 47(3): p. 849-863.
850 857	32.	
007	JZ.	Thompson, P.M., et al., Mapping adolescent brain change reveals dynamic wave

858		of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl
859		Acad Sci U S A, 2001. <b>98</b> (20): p. 11650-5.
860	33.	Thompson, P.M., et al., <i>Time-lapse mapping of cortical changes in</i>
861		schizophrenia with different treatments. Cereb Cortex, 2009. 19(5): p. 1107-
862		23.
863	34.	Fillman, S.G., et al., Elevated peripheral cytokines characterize a subgroup
864		of people with schizophrenia displaying poor verbal fluency and reduced
865		<i>Broca's area volume.</i> Mol Psychiatry, 2016. <b>21</b> (8): p. 1090-8.
866	35.	Crow, T.J., Is schizophrenia the price that Homo sapiens pays for language?
867		Schizophr Res, 1997. <b>28</b> (2-3): p. 127-41.
868	36.	Palaniyappan, L. and P.F. Liddle, Does the salience network play a cardinal
869		role in psychosis? An emerging hypothesis of insular dysfunction. J Psychiatry
870		Neurosci, 2012. <b>37</b> (1): p. 17-27.
871	37.	Del Re, E.C., et al., Baseline Cortical Thickness Reductions in Clinical High
872		Risk for Psychosis: Brain Regions Associated with Conversion to Psychosis
873		Versus Non-Conversion as Assessed at One-Year Follow-Up in the Shanghai-At-
874		Risk-for-Psychosis (SHARP) Study. Schizophr Bull, 2021. 47(2): p. 562-574.
875	38.	Pantelis, C., et al., Neuroanatomical abnormalities before and after onset
876		of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet, 2003.
877		<b>361</b> (9354) : p. 281–8.
878	39.	Slifstein, M., et al., Deficits in prefrontal cortical and extrastriatal
879		dopamine release in schizophrenia: a positron emission tomographic functional
880		magnetic resonance imaging study. JAMA Psychiatry, 2015. 72(4): p. 316-24.
881	40.	Steen, R.G., et al., Brain volume in first-episode schizophrenia: systematic
882		review and meta-analysis of magnetic resonance imaging studies. Br J
883		Psychiatry, 2006. <b>188</b> : p. 510-8.
884	41.	van Erp, T.G., et al., Subcortical brain volume abnormalities in 2028
885		individuals with schizophrenia and 2540 healthy controls via the ENIGMA
886		<i>consortium.</i> Mol Psychiatry, 2016. <b>21</b> (4): p. 547-53.
887	42.	Balu, D.T., et al., Multiple risk pathways for schizophrenia converge in
888		serine racemase knockout mice, a mouse model of NMDA receptor hypofunction.
889		Proc Natl Acad Sci U S A, 2013. <b>110</b> (26): p. E2400-9.
890	43.	McCutcheon, R.A., T. Reis Marques, and O.D. Howes, Schizophrenia-An Overview.
891		JAMA Psychiatry, 2020. <b>77</b> (2): p. 201-210.
892	44.	Brugger, S.P., et al., Heterogeneity of Striatal Dopamine Function in
893		Schizophrenia: Meta-analysis of Variance. Biol Psychiatry, 2020. 87(3): p.
894		215-224.
895	45.	Banaj, N., et al., Cortical morphology in patients with the deficit and non-
896		deficit syndrome of schizophrenia: a worldwide meta- and mega-analyses. Mol
897		Psychiatry, 2023.
898	46.	Mouchlianitis, E., R. McCutcheon, and O.D. Howes, Brain-imaging studies of
899		treatment-resistant schizophrenia: a systematic review. Lancet Psychiatry,
900		2016. <b>3</b> (5): p. 451–63.
901	47.	Jiang, Y., et al., Structural and Functional MRI Brain Changes in Patients

902		with Schizophrenia Following Electroconvulsive Therapy: A Systematic Review.
903		Curr Neuropharmacol, 2022. <b>20</b> (6): p. 1241-1252.
904	48.	Wang, J., et al., ECT-induced brain plasticity correlates with positive
905		symptom improvement in schizophrenia by voxel-based morphometry analysis of
906		<i>grey matter.</i> Brain Stimul, 2019. <b>12</b> (2): p. 319-328.
907	49.	Jiang, Y., et al., Insular changes induced by electroconvulsive therapy
908		response to symptom improvements in schizophrenia. Prog Neuropsychopharmacol
909		Biol Psychiatry, 2019. <b>89</b> : p. 254-262.
910	50.	Ho, B.C., et al., Long-term antipsychotic treatment and brain volumes: a
911		longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry, 2011.
912		<b>68</b> (2): p. 128–37.
913	51.	Lewandowski, K.E., et al., Neuroprogression across the Early Course of
914		<i>Psychosis.</i> J Psychiatr Brain Sci, 2020. <b>5</b> .
915	52.	Tanaka, S.C., et al., <i>A multi-site, multi-disorder resting-state magnetic</i>
916		resonance image database. Sci Data, 2021. <b>8</b> (1): p. 227.
917	53.	Keator, D.B., et al., The Function Biomedical Informatics Research Network
918		Data Repository. Neuroimage, 2016. <b>124</b> (Pt B): p. 1074-1079.
919	54.	Gollub, R.L., et al., <i>The MCIC collection: a shared repository of multi-modal</i> ,
920		multi-site brain image data from a clinical investigation of schizophrenia.
921		Neuroinformatics, 2013. 11(3): p. 367-88.
922	55.	Alpert, K., et al., The Northwestern University Neuroimaging Data Archive
923		<i>(NUNDA).</i> Neuroimage, 2016. <b>124</b> (Pt B): p. 1131-1136.
924	56.	Kogan, A., et al., Northwestern University schizophrenia data sharing for
925		SchizConnect: A longitudinal dataset for large-scale integration. Neuroimage,
926		2016. <b>124</b> (Pt B): p. 1196-1201.
927	57.	Poldrack, R.A., et al., A phenome-wide examination of neural and cognitive
928		function. Sci Data, 2016. 3: p. 160110.
929	58.	Repovs, G. and D.M. Barch, Working memory related brain network connectivity
930		in individuals with schizophrenia and their siblings. Front Hum Neurosci,
931		2012. <b>6</b> : p. 137.
932	59.	Soler-Vidal, J., et al., Brain correlates of speech perception in
933		schizophrenia patients with and without auditory hallucinations. PLOS ONE,
934		2022. <b>17</b> (12): p. e0276975.
935	60.	Kay, S.R., A. Fiszbein, and L.A. Opler, <i>The positive and negative syndrome</i>
936		scale (PANSS) for schizophrenia. Schizophr Bull, 1987. <b>13</b> (2): p. 261-76.
937	61.	Lindenmayer, J.P., R. Bernstein-Hyman, and S. Grochowski, <i>Five-factor model</i>
938		of schizophrenia. Initial validation. J Nerv Ment Dis, 1994. <b>182</b> (11): p. 631-
939		8.
940	62.	Rolls, E.T., et al., <i>Automated anatomical labelling atlas 3.</i> Neuroimage, 2020.
941	/	<b>206</b> : p. 116189.
942	63.	Pomponio, R., et al., <i>Harmonization of large MRI datasets for the analysis</i>
943		of brain imaging patterns throughout the lifespan. Neuroimage, 2020. 208: p.
944		116450.
945	64.	Desikan, R.S., et al., An automated labeling system for subdividing the human
~ 10	~ 14	

946		cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage,
947		2006. <b>31</b> (3): p. 968–80.
948	65.	Iglesias, J.E., et al., A computational atlas of the hippocampal formation
949		using ex vivo, ultra-high resolution MRI: Application to adaptive segmentation
950		of in vivo MRI. Neuroimage, 2015. 115: p. 117-37.
951	66.	Saygin, Z.M., et al., <i>High-resolution magnetic resonance imaging reveals</i>
952		nuclei of the human amygdala: manual segmentation to automatic atlas.
953		Neuroimage, 2017. 155: p. 370-382.
954	67.	Iglesias, J.E., et al., A probabilistic atlas of the human thalamic nuclei
955		combining ex vivo MRI and histology. Neuroimage, 2018. 183: p. 314-326.
956	68.	Iglesias, J.E., et al., Bayesian segmentation of brainstem structures in MRI.
957		Neuroimage, 2015. <b>113</b> : p. 184-95.
958		








Figure 1. Two pathophysiological progression trajectories in schizophrenia. (a) Dice coefficient indicates that K=2 is the optimal number of subtypes with best consistency of the subtype labeling between two independent schizophrenia populations using non-overlap 2-folds cross-validation procedure. Data are presented as mean values +/-SD. (b) The proportion of individuals whose subtype labels keep consistent by non-overlap cross-validation procedure. (c) Sequences of regional volume loss across seventeen brain regions for each 'trajectory' via SuStaIn are shown in y-axis. The heatmap shows regional volume loss in which biomarker (y-axis) in a particular 'temporal' stage (T0-T16) in the trajectory (x-axis). The Color bar represents the degree of gray matter volume (GMV) loss in schizophrenia relative to healthy controls (i.e., z score). (d) Spatiotemporal pattern of pathophysiological 'trajectory'. The z-score images are mapped to a glass brain template for visualization. Spatiotemporal pattern of gray matter loss displays a progressive pattern of spatial extension along with later 'temporal' stages of pathological progression, that is distinct between trajectories. (e-f) Pathological stages of SuStain are correlated with reduced gray matter volume of Broca's area and hippocampus. (g-i) Pathological stages of SuStaIn are correlated with longer disease duration, worse negative symptoms and worse cognitive symptoms.






(c) Similarity of the trajectories among people from different parts of the world





spatiotemporal pattern of each 'trajectory' between any two of cohorts is shown by the heatmap. The color bar of the heatmap represents the similarity, which is quantified via the Spearman correlation coefficient between the trajectories from two cohorts. A total of six location cohorts are classified by where the sample locate at, including the EAS, EUR, China, Japan, Europe and North American. The whole sample is labelled as a cross-ancestry cohort.



**Figure 3. Subtype-specific signatures in neuroanatomical pathology.** Regional Morphological z-scores (i.e., normative deviations from healthy control group) for each subtype are mapped to a brain template for visualization. Effect size of inter-subtype difference is quantified using Cohen's d.






Figure 4. Symptomatic trajectories across three stages of disease duration. Individuals of each subtype are divided into three subgroups according to their illness durations (early stage:  $\leq$ 2 years; middle stage: 2-10 years; late stage: >10 years). Data are presented as mean values +/- se. \* *p*<0.05.




Extend Data Fig 1. Pathophysiological progression trajectories in first-episode population and medication-naïve population. Trajectories are repeated based on the subsample data from the first-episode schizophrenia patients whose illness duration was less than two years (N=1,112, 513 females, mean age= $25.4\pm12.4$  years), and another subsample data from medication-naïve patients with schizophrenia (N=718, 353 females, mean age= $23.7\pm12.1$  years).




### Extend Data Fig 2. Comparisons of morphological z-score between the two


**subtypes**. A larger positive z-score indicates a larger deviation of reduction relative to healthy control group. Two sample t test is conducted to examine inter-subtype difference for the (a) averaged cortical volume (t=9.36, p<10e-16, Cohen's d=0.446); (b) averaged cortical area (t=8.09, p<10e-16, Cohen's d=0.386); (c) averaged cortical thickness (t=1.29, p=0.198, Cohen's d=0.061); (d) thalamus volume (t=-4.28, p=1.97e-5, Cohen's d=-0.205); (e) brain stem volume (t=-9.79, p<10e-16, Cohen's d=-0.469); (f) hippocampus volume (t=-9.25, p<10e-16, Cohen's d=-0.449); (g) amgydala volume (t=-7.83, p=8.44e-15, Cohen's d=-0.379); (h) accumbens volume (t=-6.40, p=1.94e-10, Cohen's d=-0.305); (i) caudate volume (t=-9.82, p<10e-16, Cohen's d=-0.468); (j) putamen volume (t=-8.14, p<10e-16, Cohen's d=-0.389).



**Extend Data Fig 3. Hippocampus subregional morphological z-score for the two subtypes**. A larger positive z-score indicates a larger deviation of reduction relative to healthy control group.



**Extend Data Fig 4. Amygdala subregional morphological z-score for the two subtypes**. A larger positive z-score indicates a larger deviation of reduction relative to healthy control group.



Extend Data Fig 5. Geographic map of included datasets.